Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model

Neoplasia

Volumn 9, Issue 1, 2007, Pages 47-56

  Telang, Sucheta ^a   Clem, Amy L ^a   Eaton, John W ^a   Chesney, Jason ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Angiogenesis; Ascorbic acid; Collagen; Prolyl hydroxylase; Tumor

Indexed keywords

ASCORBIC ACID; COLLAGEN TYPE 4; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BLEEDING; CELL MIGRATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBE; TUMOR GROWTH;

EID: 33846844839     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06664     Document Type: Article

References (49)

1. Chatterjee I (1970). Biosynthesis of ascorbic acid in animals. Methods Enzymol 18A, 28-34.
2. Grollman AP and Lehninger AL (1957). Enzymic synthesis of L-ascorbic acid in different animal species. Arch Biochem Biophys 69, 458-467.
3. Lind J (1753). A Treatise on the Scurvy.
4. Hodges RE, Hood J, Canham JE, Sauberlich HE, and Baker EM (1971). Clinical manifestations of ascorbic acid deficiency in man. Am J Clin Nutr 24, 432-443.
5. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
6. Bonanno E, Iurlaro M, Madri JA, and Nicosia RF (2000). Type IV collagen modulates angiogenesis and neovessel survival in the rat aorta model. In Vitro Cell Dev Biol Anim 36, 336-340.
7. Myllylä Raili E-RK-SaKIK (1978). The role of ascorbate in the prolyl hydroxylase reaction. Biochem Biophys Res Commun 83, 441-448.
8. De la Fuente M and Victor VM (2001). Ascorbic acid and N-acetylcysteine improve in vitro the function of lymphocytes from mice with endotoxin-induced oxidative stress. Free Radic Res 35, 73-84.
9. Jeng KC, Yang CS, Siu WY, Tsai YS, Liao WJ, and Kuo JS (1996). Supplementation with vitamins C and E enhances cytokine production by peripheral blood mononuclear cells in healthy adults. Am J Clin Nutr 64, 960-965.
10. Naidu KA (2003). Vitamin C in human health and disease is still a mystery? An overview. Nutr J 2, 7.
11. Cameron E and Pauling L (1974). The orthomolecular treatment of cancer: I. The role of ascorbic acid in host resistance. Chem Biol Interact 9, 273-283.
12. Cameron E, Pauling L, and Leibovitz B (1979). Ascorbic acid and cancer: a review. Cancer Res 39, 663-681.
13. Campbell JD, Cole M, Bunditrutavorn B, and Vella AT (1999). Ascorbic acid is a potent inhibitor of various forms of T cell apoptosis. Cell Immunol 194, 1-5.
14. Knowles HJ, Raval RR, Harris AL, and Ratcliffe PJ (2003). Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63, 1764-1768.
15. Maeda N, Hagihara H, Nakata Y, Hiller S, Wilder J, and Reddick R (2000). Aortic wall damage in mice unable to synthesize ascorbic acid. Proc Natl Acad Sci USA 97, 841-846.
16. Taetle R, Rosen F, Abramson I, Venditti J, and Howell S (1987). Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep 71, 297-304.
17. Omaye ST, Turnbull JD, and Sauberlich HE (1979). Selected methods for the determination of ascorbic acid in animal cells, tissues, and fluids. Methods Enzymol 62, 3-11.
18. Matkowskyj KA, Cox R, Jensen RT, and Benya RV (2003). Quantitative immunohistochemistry by measuring cumulative signal strength accurately measures receptor number. J Histochem Cytochem 51, 205-214.
19. Matkowskyj KA, Schonfeld D, and Benya RV (2000). Quantitative immunohistochemistry by measuring cumulative signal strength using commercially available software Photoshop and MATLAB. J Histochem Cytochem 48, 303-312.
20. Clement PM, Hanauske-Abel HM, Wolff EC, Kleinman HK, and Park MH (2002). The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer 100, 491-498.
21. Jaffe EA, Hoyer LW, and Nachman RL (1973). Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 52, 2757-2764.
22. Sadler JE (1991). von Willebrand factor. J Biol Chem 266, 22777-22780.
23. Cameron E and Campbell A (1974). The orthomolecular treatment of cancer: II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9, 285-315.
24. Cameron E and Pauling L (1976). Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73, 3685-3689.
25. Cameron E and Pauling L (1978). Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 75, 4538-4542.
26. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, and Frytak S (1979). Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301, 687-690.
27. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, and Ames MM (1985). High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312, 137-141.
28. Padayatty SJ and Levine M (2000). Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr 19, 423-425.
29. Padayatty SJ and Levine M (2001). New insights into the physiology and pharmacology of vitamin C. CMAJ 164, 353-355.
30. Gimbrone MA Jr, Leapman SB, Cotran RS, and Folkman J (1972). Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136, 261-276.
31. Ferrara N and Davis-Smyth T (1997). The biology of vascular endothelial growth factor. Endocr Rev 18, 4-25.
32. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
33. Millauer B, Shawver LK, Plate KH, Risau W, and Ullrich A (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
34. Stolman JMGHM and Gould BS (1961). Ascorbic acid and blood vessels. Arch Pathol 72, 59-69.
35. Mahmoodian F and Peterkofsky B (1999). Vitamin C deficiency in guinea pigs differentially affects the expression of type IV collagen, laminin, and elastin in blood vessels. J Nutr 129, 83-91.
36. Nicosia RF, Belser P, Bonanno E, and Diven J (1991). Regulation of angiogenesis in vitro by collagen metabolism. In Vitro Cell Dev Biol 27A, 961-966.
37. Ingber D and Folkman J (1988). Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 59, 44-51.
38. Migliozzi JA (1977). Effect of ascorbic acid on tumour growth. Br J Cancer 35, 448-453.
39. Spanheimer RG and Peterkofsky B (1985). A specific decrease in collagen synthesis in acutely fasted, vitamin C-supplemented, guinea pigs. J Biol Chem 260, 3955-3962.
40. Parsons KK, Maeda N, Yamauchi M, Banes AJ, and Koller BH (2006). Ascorbic acid-independent synthesis of collagen in mice. Am J Physiol Endocrinol Metab 290, E1131-E1139.
41. Lamagna C, Hodivala-Dilke KM, Imhof BA, and Aurrand-Lions M (2005). Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res 65, 5703-5710.
42. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, et al. (2004). Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 114, 898-907.
43. Langemann H, Torhorst J, Kabiersch A, Krenger W, and Honegger CG (1989). Quantitative determination of water- and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int J Cancer 43, 1169-1173.
44. Spielholz C, Golde DW, Houghton AN, Nualart F, and Vera JC (1997). Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. Cancer Res 57, 2529-2537.
45. Vera JC, Rivas CI, Fischbarg J, and Golde DW (1993). Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 364, 79-82.
46. Perez-Cruz I, Carcamo JM, and Golde DW (2003). Vitamin C inhibits FAS-induced apoptosis in monocytes and U937 cells. Blood 102, 336-343.
47. Carcamo JM, Pedraza A, Borquez-Ojeda O, and Golde DW (2002). Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry 41, 12995-13002.
48. Witenberg B, Kletter Y, Kalir HH, Raviv Z, Fenig E, Nagler A, Halperin D, and Fabian I (1999). Ascorbic acid inhibits apoptosis induced by X irradiation in HL60 myeloid leukemia cells. Radiat Res 152, 468-478.
49. Carr AC and Frei B (1999). Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 69, 1086-1107.